Last reviewed · How we verify
Remitch (NALFURAFINE)
Remitch (generic name: NALFURAFINE) is a nalfurafine drug. It is currently FDA-approved (first approved 2009) for Severe Pruritus.
Remitch is a small molecule intervention used to study various conditions, including Adverse Event, Peritoneal Dialysis, Moderate-to-severe Pruritus, Chronic Kidney Disease-associated Itch, and Pruritus. Remitch, also known as Nalfurafine Hydrochloride Orally Disintegrating Tablets, has been studied for its efficacy and safety in treating moderate-to-severe pruritus in patients on peritoneal dialysis.
At a glance
| Generic name | NALFURAFINE |
|---|---|
| Drug class | nalfurafine |
| Target | Kappa-type opioid receptor |
| Modality | Small molecule |
| Therapeutic area | Pain |
| Phase | FDA-approved |
| First approval | 2009 |
Approved indications
- Severe Pruritus
Common side effects
Key clinical trials
- Bioequivalence Study of Nalfurafine Hydrochloride Orally Disintegrating Tablets on Fasting and Fed in Humans (NA)
- Anrikefon vs Nalfurafine for Sleep Quality in Hemodialysis Patients With CKD-aP (PHASE4)
- Efficacy and Safety of Nalfurafine Hydrochloride ODT for Moderate-to-Severe Pruritus in Patients on Peritoneal Dialysis (NA)
- Efficacy and Safety of MT-9938 for Treatment of Uremic Pruritus in Subjects With End-stage Renal Disease Receiving Hemodialysis (PHASE2)
- A Multi-site Bridging Study of Nalfurafine Hydrochloride Orally Disintegrating Tablet (PHASE3)
- Nalfurafine Hydrochloride for Pruritus in Patients With Primary Biliary Cholangitis
- TRK-820 Study in Subjects on Hemodialysis With or Without Uremic Pruritus (PHASE1)
- Efficacy and Safety Study of TRK-820 to Treat Conventional-treatment-resistant Pruritus in Patients Receiving Hemodialysis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Remitch CI brief — competitive landscape report
- Remitch updates RSS · CI watch RSS
Frequently asked questions about Remitch
What is Remitch?
What is Remitch used for?
What is the generic name of Remitch?
What drug class is Remitch in?
When was Remitch approved?
What development phase is Remitch in?
What does Remitch target?
Related
- Drug class: All nalfurafine drugs
- Target: All drugs targeting Kappa-type opioid receptor
- Therapeutic area: All drugs in Pain
- Indication: Drugs for Severe Pruritus
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing